Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index dropping 1.5% and the Health Care Select Sector SPDR Fund (XLV) down 0.5%.
The iShares Biotechnology ETF (IBB) shed 0.3%.
In corporate news, Novo Nordisk's (NVO) shares fell 21% after the company named a new chief executive and tempered its 2025 outlook amid market challenges hurting sales of its obesity and diabetes drugs.
Merck (MRK) shares declined 3.3% after the company announced a multiyear optimization program and posted lower Q2 results.
Atossa Therapeutics (ATOS) shares rose 12% after the company said the US Food and Drug Administration issued constructive, "positive" feedback for the company's proposed dose optimization trial of (Z)-endoxifen to treat breast cancer.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。